Case Study 24.2 — Is Hypoactive Sexual Desire Disorder a Disease?

The situation

Hypoactive sexual desire disorder is defined as persistently low or absent sexual desire that causes marked distress or interpersonal difficulty, and that is not better explained by another medical or psychiatric condition, by a medication or substance, or by relationship circumstances.

That definition has been the subject of a sustained, genuine, and unresolved argument. The argument is not about whether the trials were run correctly — they were, and §24.4 rates the drug on that basis. It is about whether the category the trials enrolled into should exist at all.

This case study asks you to hold both positions well enough to state either one to its own advocates' satisfaction. That is a harder exercise than it sounds, and it is the specific skill Chapter 12 was building.

The case against the diagnosis

Sexual desire varies enormously — between people, and across a single life. It responds to sleep, stress, age, relationship duration, medication, illness, childbearing, work, and a hundred other inputs. Constructing a diagnostic category out of the low end of that distribution risks converting ordinary variation into pathology by definitional fiat.

The category's history is entangled with commercial interest. Diagnostic categories in this area have been actively promoted at moments when a product was seeking a market. Disease-awareness campaigns, funded by manufacturers, have shaped both clinical and public estimates of how common the condition is — and estimates of prevalence in this domain have varied by large factors depending on who was asking and how. When the party that benefits from a diagnosis being common is also funding the research establishing that it is common, skepticism is not paranoia; it is standard practice.

A distress-based criterion is unusually vulnerable. Most diagnoses anchor on something observable independent of the patient's beliefs about themselves. This one anchors partly on how the person feels about their own experience — and how a person feels about their desire is influenced by what they have been told is normal. Tell enough people that their level of desire is abnormally low and you will generate distress, which will then satisfy the criterion. The diagnosis can, in principle, manufacture its own denominator.

Locating a relational problem inside one person misdirects the intervention. Desire is frequently low for reasons that live in a context rather than in a receptor: an unrewarding relationship, exhaustion, an untreated mood disorder, a partner's behavior, resentment, or simply a mismatch between two people whose baseline levels differ and neither of whom is abnormal. Diagnosing one member of that pair converts a two-person situation into a one-person deficiency, and the resulting treatment is aimed at the wrong object.

And the drug's own results are evidence for the critique. The trials improved questionnaire scores modestly and did not increase satisfying sexual events. If the underlying problem were a discrete neurochemical deficiency, one might expect the behavioral endpoint to follow the instrument. It did not.

The case for the diagnosis

Distressing low desire is real, common, and durable. People who have it describe it as a significant and unwanted loss — of a part of their life, of a form of connection, of something that used to be there. That report is data. Declining to name it does not make it stop.

The distress criterion is a safeguard, not a loophole. It is exactly what prevents the category from capturing contented low desire. A person with low desire who is untroubled by it does not meet criteria and never did. The critique that the diagnosis pathologizes normal variation applies to a version of the diagnosis that does not exist — one without the distress requirement — and popular coverage that drops the criterion is the source of most of the confusion.

Every criticism above applies to conditions we treat without hesitation. Insomnia is the closest parallel. Sleep need varies enormously between people. Sleep complaints are exquisitely context-sensitive and frequently caused by circumstances rather than by pathology. The category has been marketed. Uncontrolled reports of sleep aids are dominated by placebo response. None of this has led anyone to conclude that people who cannot sleep and are distressed by it should be turned away without evaluation.

Refusing the diagnosis has its own cost, and it falls on a specific group. Women's sexual complaints have a long documented history of being classed as not-quite-medical, attributed to character or relationship or attitude, and returned to the patient as her own responsibility. A person told that their distressing complaint is merely normal variation has not been spared a diagnosis. They have been handed a different one — that their unhappiness is a personal failing — with no clinical pathway attached.

And the diagnostic exclusions do exactly what critics ask for. The criteria explicitly exclude low desire better explained by another condition, by a medication, or by relationship circumstances. The diagnostic process, applied properly, is a systematic search for the contextual causes that critics correctly identify as common. It is only when that search comes up empty and the person is still distressed that the diagnosis applies.

What the argument is actually about

Both positions have force. Notice why the dispute does not resolve.

It is not primarily an empirical disagreement. Both sides accept that desire varies, that context matters, that some people are distressed, and roughly what the trial results were. What they disagree about is where to draw a line on a continuum, and what follows from drawing it there.

Chapter 12 gave the framework: the same phenomenon can be described as disease, as behavior, or as environment. Each description assigns responsibility differently, implies a different kind of help, determines who pays, and carries a different set of second-order effects. That chapter argued about weight. This is the same argument about desire, with the same structure and the same absence of a purely empirical resolution.

What the rating system requires is that the two questions stay separate. Whether HSDD should be a diagnosis is a debate about categories. Whether bremelanotide outperformed placebo in people who met the criteria is a question about trials, and it has an answer. Rule 4 — never downgrade with distaste — exists for exactly this configuration.

Discussion questions

1. State the distress criterion, then explain precisely how each side uses it. Critics call it a vulnerability; proponents call it a safeguard. Both are describing the same clause. Which reading do you find stronger, and what would have to be true about the world for the other reading to be correct?

2. The insomnia parallel is the proponents' strongest rhetorical move. Test it seriously. List three ways the parallel holds and two ways it breaks down. Does the parallel survive the stress test, and if it does not, does its failure help the critics or is it simply irrelevant?

3. Apply Chapter 12's three frames — disease, behavior, environment — to distressing low desire in a person whose evaluation has found no medication effect, no mood disorder, and no obvious relational cause. For each frame, state who becomes responsible, what help follows, and one group who is plausibly harmed by adopting that frame. Then say whether you think one frame is more true or merely more useful.

4. The trials improved instrument scores modestly and did not increase satisfying sexual events. Critics read that as evidence the underlying construct is not a discrete deficiency. Proponents can read it several ways. Construct the best proponent response to that specific finding — and then judge whether your own constructed response is convincing or merely available.

5. A person meets HSDD criteria, is distressed, has exhausted the contextual evaluation, and asks about bremelanotide. Sketch what an honest conversation looks like. What has to be said about effect size, about nausea, about what the trials did and did not show, and about the placebo response? Then ask the harder question: does anything in the medicalization debate change what you would say to this particular person? Should it?

6. Rule 4 says never downgrade a rating with distaste. Suppose a reader is genuinely persuaded by the critics — they believe the category is an artifact of marketing. What are they still obligated to concede about the evidence, and what are they entitled to argue instead? Write two sentences that such a reader could say that would be fully consistent with the rating system, and two that would violate it.